Safe Integration of Nelarabine into Intensive Chemotherapy in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL0434

BACKGROUND: Nelarabine has shown impressive single agent clinical activity in T-cell acute lymphoblastic leukemia (T-ALL), but has been associated with significant neurotoxicities in heavily pre-treated patients. We showed previously that it was safe to add nelarabine to a BFM-86 chemotherapy backbo...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Pediatr Blood Cancer
المؤلفون الرئيسيون: Winter, Stuart S., Dunsmore, Kimberly P., Devidas, Meenakshi, Eisenberg, Nancy, Asselin, Barbara L., Wood, Brent L., Leonard, Marcia S., Murphy, John, Gastier-Foster, Julie M., Carroll, Andrew J., Heerema, Nyla A., Loh, Mignon L., Raetz, Elizabeth A., Winick, Naomi J., Carroll, William L., Hunger, Stephen P.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2015
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433576/
https://ncbi.nlm.nih.gov/pubmed/25755211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25470
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة